019175.KS KSC
Shinpoong Pharmaceutical Co.,Ltd
1W: +1.7%
1M: -10.3%
3M: +5.5%
YTD: -29.9%
1Y: -44.1%
3Y: -47.7%
5Y: -89.7%
₩14,080.00 ($10.47)
-70.00 (-0.49%)
Weekly Expected Move ±5.5%
₩12518
₩13299
₩14080
₩14861
₩15642
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$352.5B
+3.0% ▲
5Y CAGR: -6.3%
Total Liabilities
$81.7B
-2.7% ▼
5Y CAGR: -6.2%
Shareholders Equity
$270.0B
+5.1% ▲
5Y CAGR: -6.3%
Cash & Investments
$71.5B
+26.6% ▲
5Y CAGR: -17.8%
Total Debt
$55.9B
+2.3% ▲
5Y CAGR: +99.1%
Net Debt
$8.4B
-33.2% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $27.6B | $41.7B | $43.8B | $42.0B | $47.4B |
| Short-Term Investments | $65.1B | $14.2B | $16.7B | $14.5B | $24.1B |
| Cash & ST Investments | $92.7B | $55.9B | $60.5B | $56.5B | $71.5B |
| Net Receivables | $90.4B | $90.7B | $82.1B | $72.5B | $73.5B |
| Inventory | $47.7B | $46.9B | $53.9B | $55.4B | $58.5B |
| Other Current Assets | $9.8B | $10.4B | $180M | $55M | $37M |
| Total Current Assets | $227.2B | $196.5B | $198.9B | $189.3B | $206.7B |
| Property, Plant & Equip. | $116.9B | $113.8B | $118.6B | $115.4B | $108.7B |
| Goodwill & Intangibles | $9.0B | $6.9B | $5.8B | $5.0B | $5.1B |
| Long-Term Investments | -$34.7B | $17.6B | $21.1B | $12.2B | $23.1B |
| Other Non-Current Assets | $65.1B | $20.1B | $5.6B | $17.4B | $7.7B |
| Total Non-Current Assets | $165.4B | $165.0B | $151.1B | $152.8B | $145.7B |
| Total Assets | $392.6B | $361.5B | $350.1B | $342.1B | $352.5B |
| — Liabilities — | |||||
| Accounts Payable | $12.1B | $11.4B | $8.9B | $10.0B | $7.1B |
| Short-Term Debt | $248M | $0 | $45.0B | $48.7B | $44.4B |
| Deferred Revenue | $11.4B | $224M | $0 | $0 | $1.5B |
| Other Current Liabilities | $8.5B | $6.7B | $7.7B | $14.5B | $13.7B |
| Total Current Liabilities | $28.6B | $27.2B | $76.4B | $75.8B | $66.9B |
| Long-Term Debt | $0 | $0 | $0 | $4.6B | $11.4B |
| Other Non-Current Liab. | $9.3B | $3.2B | $2.7B | $3.2B | $3.3B |
| Total Non-Current Liabilities | $9.5B | $3.6B | $2.9B | $8.2B | $14.8B |
| Total Liabilities | $38.0B | $30.8B | $79.3B | $84.0B | $81.7B |
| — Equity — | |||||
| Common Stock | $26.5B | $26.5B | $27.6B | $27.6B | $27.6B |
| Retained Earnings | $139.2B | $115.8B | $50.6B | $38.9B | $46.0B |
| Accumulated OCI | -$13.4B | -$13.9B | -$18.2B | -$14.6B | -$10.7B |
| Total Stockholders Equity | $353.5B | $329.6B | $269.6B | $256.8B | $270.0B |
| Total Liabilities & Equity | $392.6B | $361.5B | $350.1B | $340.8B | $352.5B |
| — Key Metrics — | |||||
| Total Debt | $1.2B | $1.9B | $46.2B | $54.6B | $55.9B |
| Net Debt | -$26.5B | -$39.8B | $2.4B | $12.6B | $8.4B |
| Total Investments | $30.4B | $31.8B | $38.0B | $26.6B | $47.2B |